Cambridge, United States
QurAlis, founded in 2016, is a biotechnology startup located in the United States, specializing in precision medicines for neurodegenerative diseases. Their slogan, "Neuro Pioneers on a Quest to Cure," encapsulates their mission to transform the treatment landscape for diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
The company's founders, a group of neurodegenerative biologists from Harvard Medical School and Harvard University, are advancing a pipeline that targets specific ALS and FTD pathologies. The approach is based on genetic mutations and clinical biomarkers, showcasing their commitment to precision health care.
In their latest Series B funding round on 09 March 2023, QurAlis raised $88.00M from a diverse group of investors including Amgen Ventures, Polaris Partners, and Dolby Ventures, reinforcing strong confidence in their innovative therapies and market potential.
